Nonsurgical Periodontal Treatment Associated or Not With Systemic Antibiotics and Photodynamic Therapy

Universidade Estadual Paulista Júlio de Mesquita Filho

Status: Completed

Conditions: Aggressive Periodontitis, Generalized

Treatments: Drug: systemic clarithromycin; Procedure: photodynamic therapy; Procedure: periodontal debridement

Study type: Interventional

Funder types: Other

Identifiers

NCT03142776

CLMPDT

Details and patient eligibility

About

To assess the local effect of the antimicrobial therapy using clarithromycin association with photodynamic therapy (PDT) in the treatment of generalized aggressive periodontitis (GAgP).

Full description

The aim of the present study was to evaluate the local effect of the antimicrobial therapy using clarithromycin (CLM) association with photodynamic therapy (PDT) in the treatment of generalized aggressive periodontitis (GAgP). Sixty periodontal pockets were select and randomly assigned into four groups: Periodontal Debridement (PD) (n=15): periodontal pockets that received periodontal debridement (PD) with placebo; PD+CLM (n=15): periodontal pockets that received periodontal debridement associated with clarithromycin; PD+PDT (n=15): periodontal pockets that received periodontal debridement associated with photodynamic therapy; PD+CLM+PDT (n=15): periodontal pockets that received periodontal debridement associated with clarithromycin and photodynamic therapy. Probing depth (PD),gain in clinical attachment level (CAL) and bleeding on probing (BOP) were evaluated at baseline, 3 and 6 months post- operatively.

Enrollment: 60 patients

Sex: All

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnosis of GagP
• presence of ≥20 teeth
• <35 years of age
• periodontal pockets with probing depth (PD) and Clinical Attachment Level (CAL) ≥ 5mm with concomitant bleeding on probing (BOP) in single-rooted teeth from different quadrants - agree to participate in the study and sign a written consent.

Exclusion criteria

• pregnant or lactating
• suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease
• received antimicrobials in the previous 6 months
• taking long-term anti-inflammatory drugs
• received a course of periodontal treatment within the last 12 months
• smoked

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 4 patient groups, including a placebo group

Periodontal debridement

Placebo Comparator group

Description:

Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).

Treatment:

Procedure: periodontal debridement

Periodontal debridement + CLM

Active Comparator group

Description:

Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.

Treatment:

Procedure: periodontal debridement

Drug: systemic clarithromycin

Periodontal debridement + PDT

Active Comparator group

Description:

Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).

Treatment:

Procedure: periodontal debridement

Procedure: photodynamic therapy

Periodontal debridement + CLM + PDT

Active Comparator group

Description:

Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.

Treatment:

Procedure: periodontal debridement

Procedure: photodynamic therapy

Drug: systemic clarithromycin